ProStrakan signs two Sancuso marketing deals

Scottish drugmaker ProStrakan has signed two exclusive licence and supply agreements for certain countries in the Pacific Region and Turkey  for Sancuso (granisetron skin patch) for the prevention of  chemotherapy-induced nausea and vomiting in patients receiving  chemotherapy for up to five consecutive days.

Singapore-based Invida Pharmaceutical Holdings will market Sancuso in  Australia, Indonesia, the Philippines, Thailand and Vietnam, while  Dubai-based NewBridge Pharmaceuticals will sell the product in Turkey.  ProStrakan has already partnered with NewBridge for the marketing of  Sancuso in the Middle East and Africa.

Under the terms of the agreements, ProStrakan will receive undisclosed  upfront and milestone payments, subject to the achievement of certain  approvals and sales targets. Invida and NewBridge will be required to  purchase Sancuso directly from ProStrakan at a pre-agreed price.  Further financial details were not disclosed. The agent delivers  granisetron, an established 5HT3 receptor antagonist, into the  bloodstream for up to seven days and has been shown to be as  efficacious as oral granisetron in preventing CINV.